Amphastar Pharmaceuticals (AMPH) Accumulated Expenses (2013 - 2026)

Amphastar Pharmaceuticals' Accumulated Expenses history runs 14 years deep, the most recent figure standing at $117.2 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 4.82% year-over-year to $117.2 million in Q1 2026; TTM through Mar 2026 was $117.2 million, a 4.82% decrease from a year earlier, with the FY2025 full-year figure at $115.8 million, down 8.52% from the prior year.
• Accumulated Expenses advanced to $117.2 million in Q1 2026 per AMPH's latest filing, from $115.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $198.7 million in Q2 2023 and bottomed at $63.7 million in Q4 2022.
• The 5-year median for Accumulated Expenses is $115.8 million (2025), against an average of $109.3 million.
• Across the five-year window, Accumulated Expenses jumped 198.38% in 2023 and plunged 49.96% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $63.7 million in 2022, then rose by 6.57% to $67.9 million in 2023, then soared by 86.29% to $126.5 million in 2024, then fell by 8.52% to $115.8 million in 2025, then increased by 1.24% to $117.2 million in 2026.
• Per Business Quant, the three latest AMPH Accumulated Expenses figures stand at $117.2 million (Q1 2026), $115.8 million (Q4 2025), and $150.3 million (Q3 2025).